AD/PD 2021 | Functional consequences of gut microbiome alterations in PD
Rejko Krüger, MD, University of Luxembourg, Belvaux, Luxembourg, shares the findings of a study investigating gut microbial changes associated with Parkinson’s disease (PD). The study focused on patients followed in the Luxembourg Parkinson’s Disease Study as well as age/sex-matched healthy control subjects. Results show that specific microbiota species were overrepresented while others were underrepresented in PD patients. Additionally, metabolic modeling of the gut microbiomes revealed altered metabolite secretion potentials, particularly for sulfur metabolism. The analysis also identified that the abundance of certain bacteria species was associated with disease progression. This interview took place during the AD/PD™ 2021 conference.
Disclosures
RK has received research grants from Fonds National de Recherche de Luxembourg (FNR) as Coordinator of the National Centre for Excellence in Research on Parkinson’s disease (NCER-PD), Coordinator of the Study on COvid-19 National survey for assessing VIral spread by Non-affected CarriErs (CON-VINCE) and from the German Research Council (DFG; KR2119/8-1), the Michael J Fox Foundation, the European Union’s Horizon2020 research and innovation program (WIDESPREAD; CENTRE-PD; grant agreement no. 692320). RK received as well as speaker’s honoraria and/or travel grants from Abbvie, Zambon and Medtronic and he participated as PI or site-PI for industry sponsored clinical trials without receiving honoraria.
